US 11,986,650 B2
Methods and systems for treating acute heart failure by neuromodulation
Sandra Machado, Beachwood, OH (US); Marc Penn, Beachwood, OH (US); and Ali R. Rezai, Columbus, OH (US)
Assigned to The Cleveland Clinic Foundation, Cleveland, OH (US)
Filed by The Cleveland Clinic Foundation, Cleveland, OH (US)
Filed on Feb. 1, 2021, as Appl. No. 17/248,634.
Application 17/248,634 is a continuation of application No. 15/879,694, filed on Jan. 25, 2018, granted, now 10,905,873.
Application 15/879,694 is a continuation of application No. 15/334,121, filed on Oct. 25, 2016, granted, now 9,878,150, issued on Jan. 30, 2018.
Application 15/334,121 is a continuation of application No. 14/085,311, filed on Nov. 20, 2013, granted, now 9,480,790, issued on Nov. 1, 2016.
Application 14/085,311 is a continuation of application No. 13/654,525, filed on Oct. 18, 2012, granted, now 8,798,738, issued on Aug. 5, 2014.
Application 13/654,525 is a continuation of application No. 12/185,473, filed on Aug. 4, 2008, granted, now 8,818,501, issued on Aug. 26, 2014.
Application 12/185,473 is a continuation of application No. 11/951,285, filed on Dec. 5, 2007, abandoned.
Claims priority of provisional application 60/873,021, filed on Dec. 6, 2006.
Prior Publication US 2021/0154470 A1, May 27, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61N 1/365 (2006.01); A61B 18/14 (2006.01); A61M 5/142 (2006.01); A61N 1/05 (2006.01); A61N 1/36 (2006.01); A61N 1/362 (2006.01); A61B 18/00 (2006.01)
CPC A61N 1/0565 (2013.01) [A61B 18/1492 (2013.01); A61M 5/14212 (2013.01); A61N 1/0568 (2013.01); A61N 1/36114 (2013.01); A61N 1/3627 (2013.01); A61N 1/36585 (2013.01); A61B 2018/00267 (2013.01); A61B 2018/00351 (2013.01); A61B 2018/00577 (2013.01); A61B 2018/00648 (2013.01); A61B 2018/00827 (2013.01); A61B 2018/00892 (2013.01)] 10 Claims
OG exemplary drawing
 
1. A method of treating a cardiovascular medical condition, the method comprising:
positioning a treatment device in a pulmonary artery; and
neuromodulating one or more target sites of an autonomic nervous system, wherein the neuromodulating comprises applying a therapy signal from the treatment device, wherein the neuromodulating increases heart contractility between 21% and 45%.